SCHEMBL4975153

SCHEMBL4975153

COC1CCN(c2nc(Cl)nc(Cl)c2F)CC1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.34
SCD O00767 2/20 0.34
HTR6 P50406 1/20 0.34
MAP4K4 O95819 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CHRM3 P20309 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
ACACB O00763 1/20 0.33
PDE10A Q9Y233 2/20 0.32
PIK3CA P42336 3/20 0.32
MTOR P42345 2/20 0.32
ATR Q13535 1/20 0.31
ATRIP Q8WXE1 1/20 0.31
CHRM4 P08173 1/20 0.31
AOC3 Q16853 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4971895 0.84 CHRM3 (0.38) CHRM3PDE4APDE4BPDE4CPDE4D
SCHEMBL25488821 0.81 MAOB (0.39) MAOBSMN1; SMN2SCDHTR6MAP4K4
SCHEMBL4984014 0.80 JAK2 (0.43) ACACBPIK3CA
SCHEMBL4973192 0.76 KDM4E (0.38) SMN1; SMN2ALDH1A1CHRM3PDE4APDE4B
SCHEMBL25488920 0.74 MAOB (0.35) MAOBSMN1; SMN2HTR6MAP4K4ALDH1A1
SCHEMBL4973335 0.73 AOC3 (0.34) MAOBSMN1; SMN2SCDHTR6PIK3CA
SCHEMBL2337541 0.72 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1PIK3CA
SCHEMBL4974698 0.71 SMN1; SMN2 (0.35) SMN1; SMN2PDE10AATRATRIP
SCHEMBL27978720 0.70 CHRM4 (0.47) SMN1; SMN2CHRM4
SCHEMBL26604072 0.68 LMNA (0.48) SMN1; SMN2MAP4K4ATRATRIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008132502-A1 PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-11-06 WO disclosed